A Phase I/II, multicenter, open-label study is assessing the combination of oral FGF401, an FGFR4 inhibitor, with spartalizumab in refractory HCC patients harboring FGFR4 and KLB (an FGF19 co- receptor) expression and FGF401 as single-agent in other advanced solid tumors. The gene discussed is FGF19; the disease is hepatocellular carcinoma.